Dustin Sjuts: Yes. This is Dustin. I’ll kind of handle that a little bit. I think it’s a little early to go into too many specifics on it. So I think the similarities are it’ll be the key KOLs that are going to drive kind of that our ability to build that faculty base to educate the broader market, in terms of the setup, in terms of what we’ll be looking for in that disease state, you’re going to be looking at re-treatment intervals, right? When would they like to bring those patient back? How are they handling different patient disease states, just like they did in the clinical trial with a real world setting, which allows us to have a little bit more freedom for the provider to do what they currently do, right? So as you’ll remember in our clinical trials, you had specific doses that they were using.
We’re in clinical practice, they may assess the patient, they may know that they’re €“ they’ve been on a certain toxin and now they’re going to move them to DAXI so they have more freedom. And so we’ll leverage that opportunity for real world insights to inform our broader rollout and to educate the faculty.
Douglas Tsao: Okay. Great. Thank you so much.
Mark Foley: Yes. Thanks.
Operator: We have time for one final question. Serge Belanger with Needham & Company, your line is open.
Serge Belanger: Hi, good afternoon. Thanks for squeezing me in here. I guess the first question on the DAXXIFY PrevU program, you had a great start with the initial training of 400 providers in December. Just curious if you kept that pace up through January and February and I guess how many providers you expect to well have been trained by the time you launch late in the first quarter. And then secondly in terms of therapeutic indications or there’s still plans to run a Phase 3 program in upper limb toxicity, and when could that get underway? Thanks.
Mark Foley: Great, Serge. So on the DAXXIFY PrevU program hopefully we didn’t miscommunicate on this, but the plan all along was to run the PrevU program for a quarter with a select small group of injectors, and that’s 400. So we’ve not added any additional account since we did the programs in December where we onboarded the roughly 400 accounts as part of PrevU. And the whole goal there was to get experience in a very controlled setting to figure out, what insights we can glean from again how they’re positioning this with patients, how they’re pricing it, how they’re using the product, all those things. So there have not been any additional ads as part of the PrevU program that the full commercial launch will now commence in late March, again with a focus on in-person national training.
So that will kick off now the full commercial launch. And we look forward to getting that underway in late March with a focus on our existing RHA accounts. On the therapeutic indication side, we mentioned in our prepared remarks that our goal is to use the cervical dystonia approval to build clinical experience that will help inform our future therapeutic strategy. So we think we’ll learn a lot in this small number of concentrated accounts that are used to dealing with a number of these muscle movement diseases, cervical dystonia will inform a lot around again what Dustin was mentioning previously. What is the patient response, how often do they bring them back? Are they seeing greater symptom relief during that timeframe between when they bring them back and how we think that plays.
